IMUC - ImmunoCellular Therapeutics, Ltd.

NYSE American - Nasdaq Real Time Price. Currency in USD

ImmunoCellular Therapeutics, Ltd.

30721 Russell Ranch Road
Suite 140
Westlake Village, CA 91362
United States
818-264-2300
http://www.imuc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Gary S. TitusChairman & Corp. Sec.72.25kN/A1960
Dr. Anthony J. Gringeri Ph.D.CEO, Pres & Director368.99kN/A1953
Dr. John S. Yu M.D., Ph.D.Founder & DirectorN/AN/A1964
Mr. David E. Fractor CPAChief Financial Officer202.5kN/A1960
Dr. Steven J. Swanson M.D., Ph.D.Sr. VP of Research313.57kN/A1956
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.

Corporate Governance

ImmunoCellular Therapeutics, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.